TP53突变提示贝伐珠单抗联合化疗改善晚期/复发子宫内膜癌结局
该研究为GOG-86P的探索性分析,评估TP53突变状态与晚期/复发子宫内膜癌患者接受贝伐珠单抗或替西罗莫司联合化疗后PFS和OS的关系。结果显示TP53突变患者接受贝伐珠单抗较替西罗莫司的PFS和OS改善,而野生型TP53患者两臂无显著差异。
要点
- TP53突变患者接受贝伐珠单抗较替西罗莫司的PFS和OS改善
- 野生型TP53患者两治疗臂的PFS和OS无显著差异
- TP53突变状态可能作为指导子宫内膜癌治疗选择的生物标志物
核心结论
- 探索性分析提示,对于TP53突变的晚期/复发子宫内膜癌患者,化疗联合贝伐珠单抗(而非替西罗莫司)可能改善PFS和OS。
研究设计与样本
- GOG-86P研究的探索性分析,测定TP53突变状态并与PFS和OS进行相关性分析。
主要发现
- TP53突变患者接受贝伐珠单抗较替西罗莫司的PFS:HR 0.48,95%CI 0.31-0.75。
- TP53突变患者接受贝伐珠单抗较替西罗莫司的OS:HR 0.61,95%CI 0.38-0.98。
- 野生型TP53患者两治疗臂间PFS和OS无统计学显著差异。
临床怎么用
- 对于TP53突变的晚期/复发子宫内膜癌患者,可考虑化疗联合贝伐珠单抗而非替西罗莫司。
- TP53突变状态可能作为指导治疗选择的生物标志物,但需更大规模临床研究验证。
局限性
- 本研究为探索性分析,结论需进一步临床研究证实。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Successfully combining targeted agents with chemotherapy is an important future goal for cancer therapy. However, an improvement in patient outcomes requires an enhanced understanding of the tumor biomarkers that predict for drug sensitivity. NRG Oncology/Gynecologic Oncology Group (GOG) Study GOG-86P was one of the first attempts to combine targeted agents (bevacizumab or temsirolimus) with chemotherapy in patients with advanced endometrial cancer. Herein we performed exploratory analyses to examine the relationship between mutations in TP53, the most commonly mutated gene in cancer, with outcomes on GOG-86P. METHODS: TP53 mutational status was determined and correlated with progression-free survival (PFS) and overall survival (OS) on GOG-86P. RESULTS: Mutations in TP53 were associated with improved PFS and OS for patients that received bevacizumab as compared to temsirolimus (PFS: HR 0.48, 95% CI 0.31, 0.75; OS: HR: 0.61, 95% CI 0.38, 0.98). By contrast, there was no statistically significant difference in PFS or OS between arms for cases with WT TP53. CONCLUSIONS: This exploratory study suggests that combining chemotherapy with bevacizumab, but not temsirolimus, may enhance PFS and OS for patients whose tumors harbor mutant p53. These data set the stage for larger clinical studies evaluating the potential of TP53 mutational status as a biomarker to guide choice of treatment for endometrial cancer patients. Clintrials.gov: NCT00977574.
引用
- Leslie KK, Filiaci VL, Mallen AR, et al. Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study. Gynecol Oncol. 2021. PMID: 33541735. doi:10.1016/j.ygyno.2021.01.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。